Skip to main content
Clinical Trials/JPRN-jRCT1091220148
JPRN-jRCT1091220148CompletedPhase 3

Development of Brilliant Blue G (BBG) as a new surgical dye for internal limiting membrane (ILM) staining in vitrectomy. - A new vital surgical dye for vitrectomy.

Kyushu University0 sites30 target enrollmentStarted: November 18, 2013Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
30

Study Overview

Brief Summary

A0001 was effective and safe for visualization of the ILM during vitrectomy, and there was an improvement in ease of operation.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • 1) Patients required for vitrectomy in one or both eyes
  • Primary diseases for vitrectomy are macular hole, epiretinal macular membrane, macular hole retinal detachment cased by high myopia , proliferativevitreoretinopathy, preproliferative diabetic retinopathy, diabetic macular edema, macular edema cased by occlusion of retinal vein, and stainig and peeling of internal limiting membrane in vitrectomy are necessary.
  • 2) Age : >=20 years old at the time of obtaining informed consent
  • 3) Male or female passed 2 years after menopause
  • 4) Patients comply with the schedule instructed by PI or SI
  • 5) Patients take part in this trial based on their own free will and give informed consent in written form.

Exclusion Criteria

  • 1) Vitrectomized eye.
  • 2) Has serious of digestive, circulatory, kidney, liver, or blood/coagulation complications
  • 3) Had present and past uveitis or glaucoma
  • 4) Has a history of drug hypersensitivity reactions for Triamcinolone acetonide, mydriatic, antibacterial eyedrops or local anesthetic.
  • 5) Has a history of drug or alcohol abuse
  • 6) Had taken this clinical trial
  • 7) Will take part in in another clinical trial or clinical research during this clinical trial
  • 8) Is deemed unsuitable for this trial by PI or SI

Investigators

Similar Trials

Development of Brilliant Blue G (BBG) as a... | Clinical Trial